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Mechanism and prevention of cardiac arrhythmias in chronic
hemodialysis patients. We monitored, by the Holter method, 23
clinically stable maintenance hemodialysis patients for 5 (sEM)
2 hours before hemodialysis, 5.0 0.5 hours during hemo-
dialysis, and 13 3 hours after hemodialysis. Of 23 patients, 9
(39%) had unexpected frequent or complex ventricular arrhyth-
mias recorded during and after hemodialysis with a potassium
dialysate bath concentration of 2.0 mEq/liter. Patients with ven-
tricular arrhythmias were more likely to be using digoxin (8/9 vs.
1/14) and to have evidence of left ventricular hypertrophy (9/9 vs.
7/14) than were those patients without arrhythmias. Of these 9
patients with arrhythmias, 6 underwent repeat Holter monitoring
during multiple dialysate protocols. Of the 6 patients, 4 had a
significant reduction in the frequency of ventricular ectopy when
a dialysate of 3.5 mEq/liter potassium was used (P <0.05), but of
these 6, 3 still had complex arrhythmias. The use, however, of a
3.5 mEq/liter potassium dialysate plus the administration of a
400-mg dose of quinidine sulfate orally 45 mm prior to hemo-
dialysis was successful in reducing ventricular ectopic frequency
and complexity in all the patients studied. Conclusion. Mainte-
nance hemodialysis patients using digoxin and with left ventricu-
lar hypertrophy have an unexpectedly high incidence of occult,
potentially serious, ventricular arrythmias during and after he-
modialysis, revealed by Holter monitoring. There is preliminary
evidence that a low-potassium bath concentration may play a
role in predisposing patients to these arrythmias. Further pro-
spective studies with larger number of patients will be needed,
however, to evaluate the significance of these findings.
Mécanisme et prevention des arythmies chez les malades en
hémodialyse chronique. Vingt trois malades en hCmodialyse,
clinquement stables, ont été étudiés par Ia méthode de Holter
pendant 5 2 (moyenne SEM) heures avant Ia dialyse, 5,0
0,5 heures pendant Ia dialyse et 13 3 heures après Ia dialyse.
Neufde ces vingt trois malades (39%) ont eu des arythmies yen-
triculaires imprévues, frCquentes ou complexes, pendant ou
aprCs la dialyse réalisée avec un bain contenant du potassium a
la concentration de 2 mEq/liter. Les malades qui ont eu des
arythmies sont plutôt ceux qui prennent de Ia digoxine (8/9
contre 1/14) et plutôt ceux qui ont des signes d'hypertrophie yen-
triculaire gauche (9/9 contre 7/14). Six parmi les 9 malades qui
ont eu des arythmies ont subi des etudes itératives par Ia me-
thode de Holter au cours de protocoles avec différents dialysats.
Quatre de ces 6 malades ont eu une diminution significative des
accès d'ectopie ventriculaire avec un bain a 3,5 mEq/liter de po-
tassium (P < 0,05), mais 3 sur les 6 ont encore eu des arythmies
complexes. Cependant l'emploi de 3,5 mEq/liter de potassium
associC a l'administration orale de 400 mg de sulfate de quinidine
45 mm avant l'hémodialyse a permis de rCduire Ia fréquence des
ectopies ventriculaires chez tous les malades Ctudiés. Nous con-
cluons que les malades en hémodialyse iterative qui prennent de
Ia digoxine et ceux qui sont atteints d'hypertrophie ventriculaire
gauche ont une incidence élevée d'arythmies ventriculaires Ia-
tentes et potentiellement graves, au cours et au décours de
l'hémodialyse, misc en evidence par Ia méthode de Holter, Ii
existe des arguments en faveur du role d'une concentration
faible de potassium dans le bain dans Ia genèse de ces accidents.
D'autres etudes prospectives sur un plus grand nombre de mal-
ades sont cependant nécessaires pour évaluer Ia signification de
ces constatations.
Despite significant advances in dialysis tech-
niques, patients with end-stage renal disease on
chronic maintenance hemodialysis have a yearly
mortality of 10%, which in nearly all large series is
attributable primarily to cardiovascular disease [1—
7] with congestive heart failure, cardiac arrhyth-
mias, and acute myocardial infarction responsible
for 50% of these deaths [4—6, 8—13]. This increase in
susceptibility to cardiovascular mortality is not re-
stricted to elderly patients and accounts for 50% of
the deaths in children on hemodialysis as well [14].
The actual contribution of cardiac arrhythmias to
increased cardiovascular mortality in stable end-
stage renal disease patients on chronic hemodialysis
has not been previously detailed. There is epi-
demiologic evidence, however, that the occurrence
of significant ventricular arrhythmias, particularly
in the presence of underlying heart disease, may in-
crease one's susceptibility to an arrhythmic death
[15-17]. Therefore, we undertook the following
prospective study to determine if 24-hour Holter
°monitoring could identify patients on maintenance
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hemodialysis with occult but potentially serious
ventricular arrhythmias.
Methols
Twenty-three adult patients, consisting of 11 men
and 12 women on chronic hemodialysis with a mean
age of 47 5 yr (range, 21 to 73 yr) and with diverse
etiologies for renal disease, were studied prospec-
tively after informed consent was obtained. All pa-
tients were medically stable for more than 4 months
prior to the study during ambulatory maintenance
hemodialysis at the Hospital of the University of
Pennsylvania Hemodialysis Facility, and no patient
had known ventricular arrhythmias. Using two-
channel Holter monitors (Avionics 445), we mon-
itored all patients for 24 hours, which included, on
the average, a 5-hour period before hemodialysis, a
5-hour period during hemodialysis, and a 13-hour
period after hemodialysis. A trained analyst-com-
puterized 600-A-scanner method of Holter tape
analysis was used. Its demonstrated error rate,
compared with real time, was approximately 7%
[18]. Patient data included smoking history, alco-
holic intake, medications, history of cardiac disease,
and cardiovascular symptoms. Physical examination
was done prior to and after hemodialysis to assess
the presence of murmurs, rubs, or gallops. Chest X-
rays (posterior-anterior and lateral) were evaluated
for evidence of cardiomegaly, which was defined by
a cardiothoracic ratio greater than 0.5. A standard 12-
lead electrocardiogram was evaluated for the pres-
ence of left ventricular hypertrophy, defined by a
greater than 11 mm R-wave in lead AVL [19], and
evidence for myocardial infarction, defined by the
presence of pathologic Q waves. These criteria
were selected to facilitate high specificity. M mode
echocardiography was performed to evaluate the
presence of left ventricular hypertrophy as defined
by a posterior ventricular wall thickness of 12
mm. Hemodialysis was performed for 5 hr/treat-
ment, on the average, using either a Travenol CD-
1000 or CD-1400, a C-DAK 1.3-rn2 hollow fiber kid-
ney or a Gambro 13.5-j parallel plate. Blood flow
rate was maintained at 225 to 250 mllmin with a
dialy sate flow of 300 to 500 mllrnin. A standard dex-
trose dialysate solution, Diasol® containing the fol-
lowing concentrations was used: 130 rnEq/liter so-
dium, 97.75 mEq/liter chloride, 1.5 rnEq/liter mag-
nesium, 37 mEq/liter acetate, and 250 g/liter
dextrose. The dialysate calcium and potassium con-
centrations were individualized for each patient.
The dialysate calcium ranged from 3.25 to 4.0 rnEq/
liter, and the dialysate potassium ranged from 0 to 3
mEq/liter. Samples of venous blood were obtained
prior to Holter monitoring and at the conclusion of
the hemodialysis treatment to assess hemoglobin,
hematocrit, serum electrolytes (sodium, potassium,
chloride, and carbon dioxide), BUN, creatinine,
magnesium, calcium, phosphate, cholesterol, tri-
glyceride, high-density lipoprotein, and "mixed
venous" (arterialized, drawn via the arteriovenous
hemodialysis access site) pH, P02 and Pco2. Blood
pressure and pulse were recorded every hour or
more frequently, if the patient had any symptoms of
cramps, chest pain, or palpitation. All symptoms
and complaints during hemodialysis were recorded.
For the purpose of this study, "serious ventricu-
lar arrhythmias" were defined as the presence of
one or both of the following: (1) ventricular pre-
mature depolarizations occurring at a rate of greater
than 30/hr, and (2) complex arrhythmias. Complex
ventricular arrhythmias were defined as couplets,
multiform beats, or ventricular tachycardia ( trip-
lets).
Statistics. To take into account the nonuniform
distribution of arrhythmia frequency in individual
patients, the high spontaneous variability of fre-
quency from hour to hour [18], and the small num-
ber of patients studied, we used a Kruskal-Wallis
nonparametric one-way analysis of variance applied
with a median test that determined the significance
of changes in frequency of ventricular premature
depolarizations occurring during different periods
of the study protocol. A nonpaired Student's t test
was applied to the analysis of demographic data,
risk factors, and other laboratory data.
Results
The results of Holter monitoring defined two pop-
ulations. Group 1 consisted of 14 patients without
serious arrhythmias prior to, during, or after hemo-
dialysis. Figure 1 shows the mean frequency of ven-
tricular premature depolarizations for Group 1 pa-
tients, which averaged less than 2/hr during the en-
tire 24-hour period. In addition, no patient had
complex ventricular arrhythmias noted. Group 2
consisted of 9 patients, none of whom had serious
ventricular arrhythmias during the period of mon-
itoring prior to hemodialysis (Fig. 1), but all 9 had a
statistically significant increase in the mean hourly
frequency of ventricular premature depolarizations
during dialysis and after hemodialysis, compared
with prehemodialysis monitoring. In addition, 6 of
the 9 patients had complex arrhythmias noted dur-
ing hemodialysis or after hemodialysis, or both
(Fig. 2).
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There was no significant difference noted be-
tween group I and group 2 in examining the follow-
ing demographic data: patient age, race, sex, or
number of months on dialysis (Table 1). Group 2
patients, however, had a higher prevalence of neph-
rosclerosis as their cause of renal disease (7/9 vs. 6/
14, 0.10 > P > 0.05). The diagnosis of nephroscle-
rosis was defined by the absence of evidence for
chronic glomerulonephritis or other causes for renal
disease in patients with a history of malignant hy-
pertension, hypertension of more than 10 years, or
both. Group 1 and group 2 did not differ significant-
ly in the prevalence of cardiovascular risk factors.
Half of the patients in each group had known hyper-
tension defined by a predialysis blood pressure of 
150/90 when off medication, and half smoked at
least 1 pack of cigarettes a day for more than 5
years. Only I patient out of 23 had adult-onset dia-
betes mellitus, and he was in group 1. The mean
fasting serum cholesterol and triglycerides were
less than 190 mg/dl in both group 1 and group 2, and
the mean high-density lipoprotein levels were 42
mg/dl in both populations. There was no statistical-
ly significant difference between group I and group
2 patients in the following serum values: hemoglo-
bin, hematocrit, sodium chloride, carbon dioxide,
creatinine, calcium, and phosphate either prior to
hemodialysis or after hemodialysis (Table 2). Serum
potassium concentrations were statistically (P <
0.03) higher prior to hemodialysis in group 2 pa-
tients (mean 4.9 [SEMI 0.2 mEq/liter) compared
with group 1 patients (mean 4.6 [sEMI 0.3 mEq/
liter). After hemodialysis, both groups had a
marked lowering of their serum potassium concen-
tration, with group I patients being more hypoka-
lemic (mean 3.2 [sEM] 0.1 mEq/liter) than were
group 2 patients (mean 3.5 [SEMI 0.3 mEq/liter,
0.10 > P> 0.05). Serum magnesium concentrations
and mixed venous pH determinations were mini-
mally but statistically higher (0.025 < P < 0.05) in
group 1 patients compared with group 2 patients,
although both mean values were within normal
range. Group 2 patients also had a mild but consis-
tently lower Po2 than did group 1 patients.
Certain clinical characteristics did distinguish
group I from group 2 patients and suggested the
presence of more advanced cardiovascular disease
in group 2 patients. Although there was no dif-
ference in the frequency of angina pectoris, as de-
tailed in Table 3, there was a statistically significant
difference in the prevalence of third heart sounds
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Fig. 1. Comparison of mean hourly frequencies (± SEM) ofven-
tricular premature depolarizations (VPDs) before, during, and
after hemodialysis (HD) in two populations. Group 1 (closed
bar) consisted of 14 patients without frequent or complex at-
rhythmias before, during, or after hemodialysis and group 2 (cross
hatch) consisted of 9 patients without serious arrhythmias before
hemodialysis, but with significant (P <0.02) ventricular arrhyth-
mias during and after hemodialysis. The broken bar () above
the "During HD" VPD frequency represents the large SEM (± 25
VPDs/hr). Of note, arrhythmias were infrequent during the im-
mediate predialysis period in both group 1 and group 2 patients.
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Fig. 2. Hourly frequencies of ventricular premature depoliza-
tions (VPDs) before, during, and after hemodialysis using a rou-
tine 2.0-mEqiliter potassium dialvsate in a representative group-
2 patient (patient 2 on digoxin). Asterisks (*) indicate those
hours when complex ventricular arrhythmias were recorded.
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and the presence of left ventricular hypertrophy by
echocardiography. The most sensitive indicator for
the detection of patients at risk for arrhythmias was
left ventricular hypertrophy diagnosed by a posteri-
or wall thickness of 12 mm on M mode echo-
cardiography (9/9). Electrocardiographic evidence
of left ventricular hypertrophy was much less sensi-
tive (2/9) when the strict criterion of an R wave
greater than 11 mm in lead AVL was used. There
was also a higher prevalence in the use of digoxin in
those patients with ventricular premature depolari-
zations (group 2) compared to patients without ven-
tricular premature depolarizations (group 1) (P <
0.01). The serum digoxin levels were within the
therapeutic range ( 2.0 ng/ml) both before (1.2
[SEMI 0.2 ng/ml) and after (1.3 [sEMi 0.2 nglml)
hemodialysis in all patients with arrhythmia. All pa-
tients were prescribed 0.125 mg of digoxin to be
taken every other day by mouth.
Of the 9 patients with serious ventricular arrhyth-
mias detected by Holter monitoring, 6 consented to
being remonitored while being dialyzed on the fol-
lowing four protocols: (I) against a standard potas-
sium bath concentration of 2.0 mEq/liter; (2) against
a bath with the potassium concentration increased
to 3.5 mEq/liter; '(3) against a standard potassium
bath of 2.0 mEq/liter plus an oral dose of 400 mg of
quinidine sulfate given 45 mm prior to hemo-
dialysis; and (4) against a bath potassium of 3.5
mEq/liter plus an oral dose of 400 mg of quinidine
sulfate given 45 mm prior to hemodialysis. Holter
monitors were analyzed to detect changes in hourly
ventricular premature depolarization frequency and
for the presence of complex arrhythmias. Ventricu-
Table 1. Demographic data and risk factorsa
Demographic Group 1 (N = 14) Group 2 (N 9) P
Age,yr 44.8 4.0 51.5 3.0 NS
Sex 6M18F 5M14F NS
Race 9B/5W 6B/3W NS
Etiology 6 nephrosclerosis 7 nephrosclerosis 0.10 > P> 0.05
5 chronic glomerulonephritis 1 atherosclerosis
1 systemic lupus erythematosis 1 Alport's syndrome
1 pyelonephritis
Time on HD,yr 2.5 0.5 2.6 0.6 NS
Risk factors:
Hypertension, % 46 55 NS
Smoking, % 36 55 NS
Cholesterol, mg/dl 187 9 171 15 NS
Triglyceride, tng/dl 185 29 164 35 NS
High density lipoprotein, ing/dI 42 5 42 8 NS
Diabetes, % (actual no.) 7(1/14) 0(0/14) NS
a Values are the means SEM. Abbreviations are: B, black; F, female; HD, hemodialysis, M, male, W, white.
Table 2. Laboratory dataa
Before hemodialysis After hemodialysis
Group 1 Group 2 Group 1 Group 2
Lab Test (N = 14) (N = 9) (N = 14) (N 9)
Hemoglobin,g/dl 9.3 2.4 8.6 1.3 — —
Sodium, mEqiliter 136 3.2 134 4.0 133 3.1 131 4.2
Potassium, rnEq/liter 4.6 0.3 4.9 0.2c 3.2 0.1 3.5 0.3
Chloride,mEq/liter 97 5 98 4.0 95 3.0 93 5.0
Bicarbonate,mEq/liter 19.5 2.2 17 2.5 21 4.8 19 3.8
BUN,mg/dl 75 6 93 11 40 4 52 10
Creatinine,mg/dl 18.5 1 16 2 10 1 10 2
Calcium, mg/dl 9.3 0.2 9.0 0.2 10.9 0.3 10.2 0.3
Phosphate,mg/dl 4.4 0.4 5.4 0.7 3.2 0.3 3.8 0.4
Magnesium, mg/dl 3 Ø,3d 2.7 03d — —
Mixed venous blood pH 739 0•01d 7.35 0.02" 7.45 0.01 7.44 0.02
P02, torr 93 2" 80 3b 90 4" 80 31,
Values are the means SEM.
b P < 0.01, group 1 vs. group 2.
P < 0.03, group 1 vs. group 2.
d 0.025 < P < 0.05, group 1 vs. group 2.
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lar arrhythmia frequencies during and after dialysis
on each protocol were compared to the frequencies
recorded during the period just prior to hemo-
dialysis. Patients were dialyzed at the same time of
day during each of the dialysis period throughout
this study. Serum quinidine levels were measured
just prior to hemodialysis and averaged 5 tg/ml
(range, 3.8 to 5.3 jsg/ml). Table 4 details the mean
hourly ventricular premature depolarization fre-
quencies for all six patients for the prehemodialysis
periods and for the periods during and after hemo-
dialysis on each of the four protocols.
Frequency of ventricular premature depolariza-
tions. None of the patients had frequent or complex
arrhythmias recorded before dialysis, and 5 of the 6
patients averaged five or less ventricular premature
depolarizations per hour. All patients had a marked
increase in the mean hourly frequency of ventricu-
lar premature depolarizations during hemodialysis
Table 3. Clinical characteristics
Group 1
(N=14)
Group 2
(N=9) P
Angina 4(29%) 3 ( 33%) NS
S3 gallop 0 3 ( 33%) <0.01
LVH by ECHOa 7(50%) 9(100%) <0.01
LVH by EKGb 0 2 ( 22%) NS
Digoxin 1(17%) 8 ( 89%) <0.001
Left ventricular hypertrophy (LVH) by echocardiography
(ECHO) was defined by a posterior wall thickness of 12 mm or
greater.
b Left ventricular hypertrophy by electrocardiogram (EKG)
was defined by an R wave greater than 11 mm in AVL.
when dialyzed against a standard potassium bath
concentration of 2.0 mEq!liter. For all patients, this
increase was statistically significant (P <0.05). In 4
of the 6 patients (patients I to 4), increasing the po-
tassium bath concentration to 3.5 mEq/liter was ef-
fective in decreasing the frequency of ventricular
premature depolarizations occurring during hemo-
dialysis, compared with the frequency occurring on
a routine bath potassium of 2.0 mEq!liter. In 4 of the
6 patients, this reduction in frequency was statisti-
cally significant. A 400 mg dose of quinidine sulfate
given 45 mm prior to dialysis against a routine po-
tassium bath concentration of 2.0 mEq/liter ef-
fectively decreased the mean hourly frequency of
ventricular premature depolarizations during hemo-
dialysis in 3 of the 5 patients available for restudy
(patients 1, 5, 6) (P <0.02). Patient 3, however, had
a marked and statistically significant increase in the
frequency of ventricular premature depolarizations
during hemodialysis while on quinidine sulfate, and,
of note, this patient's serum potassium level after
hemodialysis was only 2.4 mEq/liter, the lowest of
all 5 patients. The same dose of quinidine sulfate in
combination with a potassium bath of 3.5 mEq/liter
was effective in reducing the frequency of ventricu-
lar premature depolarizations occurring during he-
modialysis in 4 of the 5 patients studied (patients I,
3, 5, 6).
Complex ventricular arrhythmias. None of the 6
patients (Table 4) had complex ventricular arrhyth-
mias during any of the prehemodialysis periods. All
6 patients had complex arrhythmias reported during
Table 4. Mean hourly frequency of ventricular premature depolarizationa
Patient
no.
Before
hemodialysis"
Potassium bath of
2.0 mEq/liter
Potassium bath of
3.5 mEq/liter
Potassium bath of
2.0 mEq/liter plus
400mg of QS p.o.
Potassium bath of
3.5 mEq/liter plus
400mg of QS p.o.
1 0±0 22± 24C 0± Od 7± 9' 0± Od
2 3 1 30 16 C 4 3d 1024 502 C 36 4
3 23 4 160 129 C 21 10d C — 25 11"
4 5 3 155 179 C I i C 61 26 C —
5 5±0 53± 45C 20± 13 1± ldC 5 7"
6 3±1 77± 34C 33±45 C 14± l0"C 0± 0"
Ske 4.2 0.2 3.5 0.2 3.9 0.2 3.1 0.3 4.2 0.2
range (3.9to6.5) (2.6to4.5) (3.6to4.8) (2.4to4.0) (3.7to4.9)
a Values are the means SEM. Abbreviations are C, presence of complex arrhythmias; HD, hemodialysis; QS, quinidine sulfate.
b These values include the ventricular premature depolarization frequency for all available predialysis periods. For each patient, this
represents the average of four or five 5-hour periods.
All 6 patients had a statistically significant increase in arrhythmia frequency compared to the pre-HD period (P < 0.05 to P < 0.001).
The mean hourly frequency of ventricular premature depolarizations during dialysis against a routine potassium bath of 2.0 mEq/Iiter was
calculated from two 5-hour HD treatments.
d A statistically significant change (P < 0.05) in the frequency of ventricular premature depolarizations as compared to the frequency
of ventricular premature depolarizations during HD against the routine 2.0 mEq/liter potassium dialysate.
The serum potassium pre-HD was obtained just prior to initiation of dialysis. The serum postassium during HD was obtained at the
conclusion of the dialysis treatments.
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hemodialysis against a potassium bath of 2.0 mEq!
liter. In 4 of the 6 patients (patients 2, 4, 5, 6), com-
plex arrhythmias were recorded during hemo-
dialysis even after taking a 400-mg oral dose of
quinidine sulfate 45 mm prior to the hemodialysis
treatment. Quinidine levels (mean. 5 g/ml) were
measured prior to the onset of hemodialysis. In-
creasing the potassium bath concentration to 3.5
mEq/liter did not eliminate complex arrhythmias in
50% of the patients during hemodialysis (patients 2,
4, 6), but the combination of a single oral dose of
400 mg of quinidine sulfate plus hemodialysis
against a potassium bath of 3.5 mEq/liter eliminated
complex arrhythmias during hemodialysis in all 6
patients. There was, in addition, a high frequency of
complex arrhythmias persisting for the 10 to 12
hours after hemodialysis when a potassium bath of
2.0 mEq/liter was used with or without prior use of
quinidine sulfate. These posthemodialysis ventricu-
lar arrhythmias were virtually eliminated by the use
of a potassium bath of 3.5 mEq/liter with or without
the addition of quinidine sulfate.
In addition, 2 of the 9 patients with dialysis-re-
lated arrhythmias who were not restudied on this
protocol were considered candidates for discontin-
uing digoxin therapy, and they were then remoni-
tored. They were off digoxin for  3 weeks. One
patient had 10 (sEM) 4 ventricular ectopic beats!
hr, with frequent couplets, while on digoxin, when
dialyzed against the routine 2.0 mEq/liter potassium
bath; and he had only 2 (sEM) 1 (P 0.05) ven-
tricular ectopic beats/hr and no couplets when dia-
lyzed with the same dialysate, while off digoxin.
The other patient had 42 (5EM) 15 ventricular
ectopic beats/hr while on digoxin, when the routine
2.0 mEq!liter potassium dialysate was used, and on-
ly 4 (sEM) 2 (P < 0.05) ectopic beats/hr when the
same dialysate was used while off digoxin.
Serum electrolytes. There were no statistically
significant differences in the following serum elec-
trolyte concentrations measured before and after
hemodialysis during each of the protocol studies:
sodium, chloride, and calcium. Serum magnesium
concentrations were slightly higher before hemo-
dialysis in group 1 patients (mean 3.0 [sEM] 0.3
mg/dl) compared with group 2 (mean 2.7 [SEMI
0.3 mg!dl). Though statistically different (P < 0.05)
serum magnesium concentrations in both groups
were within the normal range of values. Group 2
serum potassium concentrations were higher before
hemodialysis (mean 4.9 [SEMI 0.2 mEq!liter) and
after hemodialysis (mean 3.5 [sEM] 0.3 mEq!liter)
compared to group 1 patients who had a mean
serum potassium concentration of 4.6 (sEM) 0.3
mEq/liter before hemodialysis and a mean serum
potassium of 3.2 + (SEM) 0.1 mEq/liter after hemo-
dialysis. The mean change in serum potassium con-
centrations in each group was 1.4 mEq/liter. The
serum potassium concentration after hemodialysis
with a bath potassium of 3.5 mEq/liter was in-
creased for the 6 patients to a mean of 4.1 (sEM)
0.2 mEq/liter (P < 0.01) with a range of 3.6 to 4.9
mEq/liter. In addition, the use of a dialysate bath
potassium of 3.5 mEq!liter also resulted in mild to
moderate hyperkalemia at 48 to 72 hours after dial-
ysis in all patients, with the mean serum potassium
value prior to the next hemodialysis increased to a
mean of 6.1 (SEM) 0.4 mEq/liter, with a range of
5.2 to 6.5 mEq!liter. This contrasted with a mean
serum potassium value of only 4.9 (5EM) 0.2 mEq!
liter (P < 0.001) (range, 3.9 to 6.1 mEq/Iiter) 48 to 72
hours after dialysis against a bath potassium of 2.0
mEq!liter.
There was no association between ventricular ar-
rhythmias and the occurrence of either clinically ap-
parent hypotension (by sphygmomanometry) or
cramps during dialysis.
Discussion
In the present study, Holter monitoring of clini-
cally stable maintenance hemodialysis patients re-
vealed serious ventricular arrhythmias occurring
during and after hemodialysis with unexpected fre-
quency. Of the 23 patients, 9 (39%) had a mean fre-
quency of 30 ventricular premature depolarizations
per hour or complex arrhythmias or both recorded
during hemodialysis. None of these patients had
frequent or complex arrhythmias during multiple 5-
hour periods of Holter monitoring prior to hemo-
dialysis treatments. Dialysis against a potassium
bath concentration of 2.0 mEq/liter resulted in the
reproducible occurrence of ventricular arrhthmias
during two separate 5-hour hemodialysis treat-
ments. These ventricular arrhythmias continued af-
ter hemodialysis, and in two thirds of the patients
they persisted for as long as 12 hours later.
Recently published studies [18] have documented
that marked spontaneous variability in ventricular
premature depolarization frequency can occur from
hour to hour. Our statistical methods took this vari-
ability into account and, in addition, considered the
fact that there was a systematic tendency for ar-
rhythmias to occur most frequently during the first
and second hours of hemodialysis, presumably
when potassium fluxes were most marked.
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Prior to this study, there have been only a few
reports on arrhythmias in hemodialysis patients.
Several investigators in the 1950's and 1960's [20—
23] detected atrial and ventricular arrhythmias on
electrocardiographic tracings during hemodialysis
in a group of acute and chronic renal failure pa-
tients. They noted that 50% of those with arrhyth-
mias were taking digoxin. They hypothesized that
rapid correction of acid-base and electrolyte abnor-
malities induced arrhythmias in patients on hemo-
dialysis who were taking digoxin.
No attempt was made by these investigators to
define further the mechanism of the arrhythmias or
to determine if arrhythmias were also present prior
to dialysis. A more recent study by Avram et al [24]
reported data on the continuous electrocardio-
graphic monitoring of dialysis patients during or
within 24 hours of starting hemodialysis. Frequent
or complex ventricular arrhythmias, or both, were
detected in more than half of their patients. These
investigators did not detect an association be-
tween the occurrence of arrhythmias and the period
of dialysis itself.
Clinical distinguishing factors. Certain clinical
characteristics did appear to distinguish the popu-
lation of dialysis patients susceptible to significant
ventricular arrhythmias. All 9 patients with arrhyth-
mias had left ventricular hypertrophy detected by
M-mode echocardiography. The use of digoxin was,
however, the most distinguishing characteristic.
These patients had been prescribed digoxin for
symptoms of congestive heart failure or cardiomeg-
aly.
Laboratory values. There were small but statisti-
cally significant differences in individual laboratory
values obtained prior to dialysis in comparing group
1 and group 2 patients. These included differences
in potassium, magnesium, calcium, and blood pH
(Table 2). None of the differences in the laboratory
values was felt, however, to be clinically important
because all were within the range of physiologic
normal values. In addition, there were no statisti-
cally significant differences in electrolyte concen-
trations or blood pH immediately after dialysis
when patients with serious ventricular arrhythmias
were compared with those without ventricular ar-
rhythmias. All patients demonstrated a lowering of
serum potassium and serum magnesium and a rise
in serum calcium and blood pH alter dialysis. Nota-
bly, group 2 patients did have a mild, but consis-
tently lower Po2 compared to group 1 patients both
before and after dialysis. Prehemodialysis P02 val-
ues did not decrease further with hemodialysis in
group 2 patients, however. Therefore, the occur-
rence of arrhythmias during and after, but not be-
fore dialysis, could not be explained by this mild
Po2 decrease. The decreased Po2 probably repre-
sented more limited cardiopulmonary reserve in
these patients.
Hypokalemia (serum potassium concentration
<3.6 mEq/liter) developed after dialysis in 10 of 14
patients without serious ventricular arrhythmias,
but only in 4 out of 9 patients with serious ventricu-
lar arrhythmias. The range of serum potassium con-
centrations after dialysis was similar between pa-
tients with (2.8 to 4.5 mEq/liter) or without (2.6 to
4.5 mEq/liter) serious ventricular arrhythmias.
Thus, hypokalemia alone was not sufficient to ac-
count for the occurrence of arrhythmias in group 2
patients.
There is evidence from previously published
studies that elevation of serum calcium and reduc-
tion of serum magnesium concentrations may also
enhance digitalis-related arrhythmias, although this
evidence is inconclusive [24-29]. Dialysis, how-
ever, may be associated both with the acute lower-
ing of magnesium and the elevation of calcium lev-
els.
Intracellular versus serum potassiumn. The devel-
opment of serious ventricular arrhythmias did not
correlate with the postdialysis serum potassium
concentrations in these 6 patients. Because the re-
moval of potassium during dialysis is most depen-
dent on the potassium gradient between the dialy-
sate and the patient's serum, and because most po-
tassium is stored intracellularly, the serum
potassium concentration during dialysis is main-
tained at the expense of intracellular potassium
stores. The serum potassium concentration in the
physiologic pH range, therefore, is not necessarily
an accurate indicator of total body potassium stores
in a dialysis patient. Marked intracellular potassium
depletion can exist despite a normal potassium con-
centration. Of the 9 patients with serious ventricu-
lar arrhythmias, 8 were on digoxin, a drug whose
action on the myocardium is affected by the
changes in both serum and total body potassium
stores. The development of frequent and complex
ventricular arrhythmias occurred most prominently
during dialysis against a potassium bath concentra-
tion of 2.0 mEq/liter (a standard dialysate concen-
tration for patients on digoxin), which results in ef-
fective removal of potassium during dialysis.
Increasing the potassium bath concentration to
3.5 mEq/liter significantly decreased the ventricular
premature depolarization frequency in 4 of the 6 pa-
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tients with serious ventricular arrhythmias com-
pared to the ventricular premature depolarization
frequency during dialysis against a bath potassium
concentration of 2.0 mEq/liter. Only half of the pa-
tients continued to have complex arrhythmias dur-
ing dialysis against an elevated bath potassium con-
centration of 3.5 mEq/liter. Raising the dialysate
potassium bath concentration to 3.5 mEq/liter,
however, did tend to result in mild hyperkalemia
prior to the next dialysis.
Because raising the dialysate potassium bath con-
centration to 3.5 mEq/liter was not sufficient to
abolish complex arrhythmias, quinidine sulfate, a
relatively safe, well-studied antiarrhythmic agent,
was added at a moderate dosage in an attempt to
better control the recurrence of significant ventricu-
lar arrhythmias. A dose of 400 mg of quinidine sul-
fate 45 mm prior to hemodialysis was sufficient to
obtain therapeutic serum quinidine levels, which
averaged 5 g/ml at the initiation of dialysis. The
combination of quinidine sulfate prior to hemo-
dialysis and a bath potassium concentration of 3.5
mEq/liter was the most effective treatment for elim-
inating both frequent and complex ventricular ar-
rhythmias.
Quinidine sulfate in combination with a bath po-
tassium of 2.0 mEq/liter did not appear to protect
patients against the development of frequent or
complex ventricular arrhythmias if significant hy-
pokalemia was present after hemodialysis. Only in
patient 1, who had a serum potassium level of 4.0
mEq/liter after hemodialysis, was quinidine suc-
cessful in eliminating ventricular arrhythmias on a
bath potassium of 2.0 mEq/liter. Antiarrhythmic
agents may not be effective in the presence of
marked hypokalemia. This combination may ac-
tually exacerbate arrhythmias. This was the case in
patient 2, who developed a marked increase in ven-
tricular arrhythmia frequency alter taking quinidine
sulfate in association with a posthemodialysis po-
tassium concentration of 2.4 mEq/liter (Table 4).
Postdialysis arrh)'t/z,nias. Frequent and complex
arrhythmias persisted for as long as 12 hours alter
dialysis when a bath potassium concentration of 2.0
mEq/liter was used. The addition of quinidine sul-
fate prior to dialysis was not sufficient to abolish
these postdialysis arrhythmias. In contrast, most
patients were back to their baseline ventricular pre-
mature depolarization frequencies within the first
hour after dialysis when a bath potassium concen-
tration of 3.5 mEq!liter was used. No complex ar-
rhythmias, however, occurred after hemodialysis
when a potassium bath concentration of 3.5 mEq/
liter was used alone or in combination with quini-
dine sulfate prior to dialysis.
Supraventricular arrhythmias. There were no
clinically important supraventricular arrhythmias
detected prior to or during hemodialysis in any of
the patients with serious ventricular arrhythmias.
One patient, however, did have frequent atrial ecto-
py (> l000/hr) for 2 to 3 hours alter hemodialysis in
association with hypotension secondary to a rup-
tured blood coil at the conclusion of the dialysis
treatment.
Thus, a population of stable chronic maintenance
hemodialysis patients had unexpected frequent and
complex ventricular arrhythmias detected by Hol-
ter monitoring when dialyzed against a routine bath
potassium concentration of 2.0 mEq/liter. Arrhyth-
mias persisted for up to 12 hours after dialysis. The
population at risk had a high prevalence of left ven-
tricular hypertrophy diagnosed by echocardiogra-
phy and electrocardiography, and the majority were
taking digoxin. Use of a dialysate bath potassium
concentration of 3.5 mEq/liter plus supplemental
oral quinidine sulfate was effective in abolishing
both frequent and complex ventricular arrhythmias
in the majority of patients both during and after
hemodialysis.
In light of the small number of patients in this
study, specific recommendations may be pre-
mature. Holter monitoring, however, may be pru-
dent for patients requiring digoxin and those with
left ventricular hypertrophy to determine if they are
susceptible to serious ventricular arrythmias occur-
ring during and after hemodialysis. Further pro-
spective studies will be required to determine if the
discontinuation of digoxin, the use of a higher than
standard potassium bath concentration, and the
possible addition of an antiarrythmic agent should
be considered for patients with the most serious
ventricular arrythmias. Certainly, further observa-
tion of these patients is warranted and indicated un-
til more specific recommendations can be made. In
addition, prospective studies using larger numbers
of patients will be required to determine whether
any therapeutic intervention designed to eliminate
serious arrythmias is also effective in reducing car-
diovascular mortality in chronic hemodialysis pa-
tients.
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